e-SPACE Heart Failure 2022
Published: 19 October 2022
37m 5sPart 1 | Session 12 Meet the expert: Sex differences in advanced heart failure
1h 1m 4sPart 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF
1h 2m 46sPart 2 | Session 1 Plenary Session 7: New technologies to manage your patients
1h 4m 11sPart 2 | Session 3 Plenary Session 8: New technologies to treat your patients
1h 9sPart 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
1h 1m 38s
1h 1m 4sPart 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
1h 1m 28sPart 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
1h 1m 14sPart 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
32m 48sPart 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
1h 22sPart 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
36m 21sPart 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
1h 1m 19sPart 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations Philippe Gabriel Steg, Shelley Zieroth, Milton Packer, Muthiah Vaduganathan, Cecilia Bahit , Subodh Verma
41m 26sPart 1 | Session 7 Satellite Symposium: SGLT2 inhibition as foundational heart failure therapy: have we changed our practices? (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Andrew JS Coats, Shelley Zieroth, Stefan Anker, Daniela Tomasoni, Clara Saldarriaga
53m 32sPart 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2) Giuseppe Galati, Altamash Y Shaikh, Ewa Jankowska, George L Bakris, Stephan Von Haehling, Javed Butler
33m 53sPart 1 | Session 9 Meet the expert: Best practice recommendations for the management of hyperkalemia (Supported by an educational grant from AstraZeneca) Clara Bonanad Lozano , Aaron Wong
34m 37sPart 1 | Session 10 Meet the expert: Hyperkalaemia in patients with heart failure – dreadful side effect or manageable condition? (Supported by an unrestricted educational grant from CSL Vifor) Javed Butler, Ileana L Piña
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Professor, Division of Cardiology
Prof Mitja Lainscak is a Professor in the Division of Cardiology at University of Ljubljana, Ljubljana, SI. He is also Director of the Slovenian Research Agency.
Assistant Professor in Internal Medicine
Dr Ambarish Pandey is an Assistant Professor in Internal Medicine at University of Texas Southwestern Medical Center, Texas, US.
He obtained his medical degree from All India Institute of Medical Sciences, India and fellowship at UT Southwestern Medical Center (2014-2018).
Dr Pandey specialises in preventive cardiology and heart failure with preserved ejection fraction.
He is a member of the American Heart Association (AHA), where he serves on several committees, including the Scientific Sessions Planning Committee and the Epidemiology Early Career Committee.
Professor of Therapeutics and Cardiology, Head of CIC
Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.
Dr. Ezekowitz, an accomplished professional in the field of cardiology, serves as the co-director of the Canadian VIGOUR Centre at the University of Alberta. He has spearheaded the establishment of five new heart failure clinics across Alberta to enhance access to specialized services. Furthermore, he plays a pivotal role in co-chairing the heart failure care pathway initiative as part of Alberta Health Services Strategic Clinical Networks.
Dr. Ezekowitz's clinical focus centers on cardiology, with a primary emphasis on heart failure. He practices at the Mazankowski Alberta Heart Institute, where he contributes to the Heart Function Clinic.
In the realm of research, Dr. Ezekowitz dedicates his efforts to acute and chronic heart failure, particularly in individuals with heart "pump" issues or end-stage heart disease. He actively engages in numerous local and international clinical trials aimed at identifying novel treatments and care strategies for heart failure…
Ileana L Piña
Dr Ileana L Pina is Professor at the Department of Medicine (Cardiology) and Professor in the Department of Epidemiology and Population Health at Montefiore Einstein Center for Heart and Vascular Care, US.
Dr Piña has a particular research and clinical interest in rehabilitation of heart disease in patients with heart failure. She completed a NHLBI HF ACTION trial and is in the process of examining recovery after exercise which could be translated to an additional parameter that may better predict prognosis of outcomes. In addition, there was a R21 to NHLBI to examine Vitamin D levels as another predictor from the HF ACTION database.
Dr Ileana L Pina is an Editorial Board member of Cardiac Failure Review.
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…